Advertisement
Screener

RAFAEL HOLDINGS, INC. (RFL) Interest Expense

2.8 / 5 stars · 68/120 Roast Me

RAFAEL HOLDINGS, INC. Interest Expense

RAFAEL HOLDINGS, INC. (RFL) reported Interest Expense of $160.00 thousand for the 3-month period ending 2025-10-31, per its 10-Q filed 2025-12-12.

Financial Statements › Expense Statement › Interest Expense

us-gaap:InterestExpense · last filed 2025-12-12

  • RAFAEL HOLDINGS, INC. interest expense for the quarter ending 2025-10-31 was $160.00K, a 1.23% decline year-over-year.
  • RAFAEL HOLDINGS, INC. interest expense for the quarter ending 2025-07-31 was $168.00K, a 3.07% increase year-over-year.
  • RAFAEL HOLDINGS, INC. interest expense for the quarter ending 2025-04-30 was $165.00K, a 94.12% increase year-over-year.
  • RAFAEL HOLDINGS, INC. interest expense for the quarter ending 2025-01-31 was $163.00K.
  • RAFAEL HOLDINGS, INC. interest expense for fiscal 2025 was $658.00K, a 165.32% increase from fiscal 2024.
  • RAFAEL HOLDINGS, INC. interest expense for fiscal 2024 was $248.00K.
  • RAFAEL HOLDINGS, INC. interest expense for fiscal 2022 was $6.00K, a 50.00% decline from fiscal 2021.
  • RAFAEL HOLDINGS, INC. interest expense for fiscal 2021 was $12.00K.
Period endInterest Expense 3 monthInterest Expense 3 month as first filedInterest Expense 6 monthInterest Expense 9 monthInterest Expense 9 month as first filedInterest Expense 12 month
2025-10-31$160.00K
10-Q · filed 2025-12-12
$328.00K
derived: sum of 2 quarters · filed 2025-12-12
$493.00K
derived: sum of 3 quarters · filed 2025-12-12
$656.00K
derived: sum of 4 quarters · filed 2025-12-12
2025-07-31$168.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-29
$333.00K
derived: sum of 2 quarters · filed 2025-10-29
$496.00K
derived: sum of 3 quarters · filed 2025-10-29
$658.00K
10-K · filed 2025-10-29
2025-04-30$165.00K
10-Q · filed 2025-06-11
$328.00K
derived: sum of 2 quarters · filed 2025-06-11
$490.00K
10-Q · filed 2025-06-11
$653.00K
derived: sum of 4 quarters · filed 2025-12-12
2025-01-31$163.00K
10-Q · filed 2025-03-14
$325.00K
10-Q · filed 2025-03-14
$488.00K
derived: sum of 3 quarters · filed 2025-12-12
$573.00K
derived: sum of 4 quarters · filed 2025-12-12
2024-10-31$162.00K
10-Q · filed 2025-12-12
$325.00K
derived: sum of 2 quarters · filed 2025-12-12
$410.00K
derived: sum of 3 quarters · filed 2025-12-12
2024-07-31$163.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-29
$248.00K
derived: sum of 2 quarters · filed 2025-10-29
$248.00K
10-K · filed 2025-10-29
2024-04-30$85.00K
10-Q · filed 2025-06-11
$85.00K
10-Q · filed 2025-06-11
2022-07-31-$13.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-30
-$12.00K
derived: sum of 2 quarters · filed 2023-10-30
-$12.00K
derived: sum of 3 quarters · filed 2023-10-30
$6.00K
10-K · filed 2023-10-30
2022-04-30$1.00K
10-Q · filed 2023-06-13
$399.00K
10-Q · filed 2022-06-14
$1.00K
derived: sum of 2 quarters · filed 2023-06-13
$19.00K
10-Q · filed 2023-06-13
$1.21M
10-Q · filed 2022-06-14
$21.00K
derived: sum of 4 quarters · filed 2023-06-13
2022-01-31$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-03-14
$13.00K
10-Q · filed 2023-03-14
$20.00K
derived: sum of 3 quarters · filed 2023-03-14
$23.00K
derived: sum of 4 quarters · filed 2023-03-14
2021-10-31$13.00K
10-Q · filed 2022-12-13
$20.00K
derived: sum of 2 quarters · filed 2022-12-13
$23.00K
derived: sum of 3 quarters · filed 2022-12-13
2021-07-31$7.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-10-31
$10.00K
derived: sum of 2 quarters · filed 2022-10-31
$12.00K
10-K · filed 2022-10-31
2021-04-30$3.00K
10-Q · filed 2022-06-14
$5.00K
10-Q · filed 2022-06-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
Aditxt, Inc. (ADTX)United States$0.000B
CDT Equity Inc. (CDT)United States$0.000B-0.01
Protagenic Therapeutics, Inc.\new (PTIX)United States$0.001B
Decoy Therapeutics Inc. (DCOY)United States$0.002B-0.27
Nexentis Technologies Inc. (NXTS)$0.002B
ORAGENICS INC (OGEN)United States$0.002B
JUPITER NEUROSCIENCES, INC. (JUNS)United States$0.002B-0.02
BioXcel Therapeutics, Inc. (BTAI)United States$0.002B
ZyVersa Therapeutics, Inc. (ZVSA)United States$0.002B
Matinas BioPharma Holdings, Inc. (MTNB)United States$0.003B